Xencor (XNCR) Shares Outstanding (Diluted Average) (2013 - 2026)
Xencor (XNCR) reported Shares Outstanding (Diluted Average) of $75.2 million for Q1 2026, up 2.14% year-over-year from $73.7 million in Q1 2025, and up 1.36% quarter-over-quarter from $74.2 million in Q4 2025.
Xencor (XNCR) Shares Outstanding (Diluted Average) (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Shares Outstanding (Diluted Average) data on file, last reported at $75.2 million in Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $75.2 million, up 2.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.2 million (up 2.14% YoY), and the FY2025 annual result was $74.2 million, up 14.14% from the prior year.
- Shares Outstanding (Diluted Average) climbed to $75.2 million in Q1 2026 per XNCR's latest filing, from $74.2 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $75.2 million in Q1 2026 and troughed at $59.5 million in Q2 2022.
- A 5-year average of $64.8 million and a median of $61.2 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) fell 2.14% in 2023, then grew 20.39% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $59.7 million in 2022, then advanced by 1.43% to $60.5 million in 2023, then advanced by 7.5% to $65.0 million in 2024, then advanced by 14.14% to $74.2 million in 2025, then advanced by 1.36% to $75.2 million in 2026.
- Business Quant data shows XNCR's Shares Outstanding (Diluted Average) at $75.2 million in Q1 2026, $74.2 million in Q4 2025, and $74.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 75.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.25 Mn |
| Dec 31, 2025 | 74.24 Mn |
| Sep 30, 2025 | 74.41 Mn |
| Jun 30, 2025 | 73.98 Mn |
| Mar 31, 2025 | 73.67 Mn |
| Dec 31, 2024 | 65.04 Mn |
| Sep 30, 2024 | 62.31 Mn |
| Jun 30, 2024 | 61.44 Mn |
| Mar 31, 2024 | 61.21 Mn |
| Dec 31, 2023 | 60.50 Mn |
| Sep 30, 2023 | 60.39 Mn |
| Jun 30, 2023 | 59.81 Mn |
| Mar 31, 2023 | 59.77 Mn |
| Dec 31, 2022 | 59.65 Mn |
| Sep 30, 2022 | 59.72 Mn |
| Jun 30, 2022 | 59.49 Mn |
| Mar 31, 2022 | 61.08 Mn |
| Dec 31, 2021 | 60.50 Mn |
| Dec 31, 2020 | 57.21 Mn |
| Mar 31, 2020 | 56.95 Mn |